간암 치료제 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 암 유형별, 기기별, 연령별, 요인별, 투여 경로별, 유통 채널별, 지역별 및 경쟁 상황(2021-2031년)

The Global Liver Cancer Therapeutics Market is projected to expand from USD 4.11 Billion in 2025 to USD 6.94 Billion by 2031, reflecting a CAGR of 9.12%. This market encompasses pharmacological interventions, including targeted therapies, immunotherapies, and chemotherapeutic agents, designed to treat hepatocellular carcinoma and intrahepatic bile duct cancers. Growth is primarily driven by the rising global incidence of chronic Hepatitis B and C infections, along with the increasing prevalence of non-alcoholic fatty liver disease linked to metabolic syndromes. Furthermore, increased healthcare expenditure and an aging population are supporting robust demand for advanced clinical solutions, ensuring growth beyond temporary trends.

Conversely, the substantial costs associated with innovative biologic treatments and combination regimens present a major obstacle to market growth, restricting patient access particularly in developing economies. This economic challenge is compounded by the high frequency of late-stage diagnoses, which limits the utility of curative interventions and strains healthcare budgets. According to the American Cancer Society, liver cancer caused over 700,000 deaths globally in 2024. This statistic highlights the urgent necessity for cost-effective therapeutic advancements to address the high mortality rates associated with the disease.

Market Driver

The market's expansion is fundamentally propelled by the significant burden of chronic Hepatitis B and C viral infections, which act as the leading causes of hepatocellular carcinoma worldwide. As chronic viral hepatitis progresses to liver cirrhosis and malignancy, it creates a continuous need for long-term management and pharmacological intervention, directly driving the demand for antiviral and antineoplastic treatments. According to the World Health Organization's 'Global Hepatitis Report 2024' released in April 2024, approximately 254 million people were living with chronic hepatitis B and 50 million with hepatitis C globally in 2022, underscoring the vast population requiring disease-modifying therapies and surveillance.

Simultaneously, the sector is being reshaped by the accelerated adoption of novel immunotherapy and combination regimens, which have largely superseded older systemic agents as the standard of care for unresectable disease. Pharmaceutical developers are actively commercializing checkpoint inhibitors that offer superior survival rates, leading to rapid uptake in developed economies. For instance, AstraZeneca reported in its 'Q3 2024 Results' in November 2024 that the immunotherapy agent Imfinzi generated $1.6 billion in sales in the third quarter alone, a 31% year-over-year increase driven by oncology demand. This surge in biologic utilization coincides with persistent diagnostic rates; the American Cancer Society's 'Cancer Facts & Figures 2024' projected 41,630 new cases of liver and intrahepatic bile duct cancer in the US for the year, reinforcing the critical need for these advanced options.

Market Challenge

The significant financial burden associated with biologic treatments and combination regimens serves as a primary restraint on the global liver cancer therapeutics market. High drug development and manufacturing expenses result in elevated pricing for end users, which limits patient access, particularly in developing regions with inadequate healthcare reimbursement frameworks. When pharmacological interventions are priced beyond the reach of public health budgets and individual patients, adoption rates slow considerably. This economic barrier prevents the widespread utilization of clinical solutions, thereby reducing potential revenue streams for manufacturers and stalling market expansion.

This challenge is further compounded when the high cost per patient is multiplied by the significant prevalence of the disease. The market faces a dichotomy where demand is robust due to incidence rates, yet the economic feasibility for widespread treatment remains low. According to the American Cancer Society, an estimated 41,630 new cases of liver cancer were diagnosed in the United States in 2024. The cumulative cost required to treat such a volume of patients with premium-priced therapeutics places immense pressure on insurance providers and national health systems. Consequently, payers often implement strict reimbursement criteria, which limits the addressable market size and hampers the overall growth trajectory of the industry.

Market Trends

The Convergence of Locoregional and Systemic Therapies is rapidly transforming the treatment landscape, specifically for patients with intermediate-stage hepatocellular carcinoma who were historically managed with catheter-based interventions alone. This trend involves the integration of systemic immunotherapies directly with transarterial chemoembolization (TACE) to reduce the high rates of disease recurrence associated with embolization monotherapy. By introducing biologic agents earlier in the treatment continuum, clinicians aim to target micrometastatic disease and improve long-term outcomes. According to The Lancet in January 2025, the 'EMERALD-1 study results' showed that the combination of durvalumab, bevacizumab, and TACE achieved a median progression-free survival of 15.0 months, a statistically significant improvement over the standard TACE protocol, effectively expanding the utilization of advanced therapeutics.

Simultaneously, the market is witnessing the resurgence and evolution of Next-Generation Oral Tyrosine Kinase Inhibitors (TKIs), which are establishing new efficacy benchmarks particularly when utilized in novel combination strategies. Unlike legacy systemic agents, these modern small molecule inhibitors are being paired with checkpoint inhibitors to deliver extended survival benefits that challenge historical clinical ceilings in unresectable disease. This trend highlights the continued relevance of kinase inhibitors as a cornerstone of therapy. According to The ASCO Post in October 2025, the 'CARES-310 trial final analysis' reported that the combination of the tyrosine kinase inhibitor rivoceranib and camrelizumab demonstrated a median overall survival of 23.8 months, the longest duration reported for any treatment in a global Phase 3 study for this indication, underscoring the revitalized role of targeted oral agents.

Key Market Players

• Bayer AG
• Bristol Myers Squibb
• Merck & Co., Inc.
• Exelixis, Inc.
• Eisai Co., Ltd.
• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• Eli Lilly and Company
• Novartis AG
• AstraZeneca PLC

Report Scope

In this report, the Global Liver Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Liver Cancer Therapeutics Market, By Cancer Type

• Hepatocellular Carcinoma
• Cholangiocarcinoma
• Liver Metastasis
• Hepatoblastoma
• Angiosarcoma

Liver Cancer Therapeutics Market, By Therapy

• Targeted Therapy
• Radiation and Chemotherapy Therapy
• Immunotherapy
• Others

Liver Cancer Therapeutics Market, By Equipment

• Computed Radiography
• MRI
• Sonography
• Others

Liver Cancer Therapeutics Market, By Age

• 0-18
• 18-35
• 35-50
• 50+

Liver Cancer Therapeutics Market, By Factors

• Non-Alcoholic Fatty Liver Disease
• Cirrhosis
• Excessive Liver Consumption
• Others

Liver Cancer Therapeutics Market, By Route of Administration

• Oral
• Intra-Venous
• Others

Liver Cancer Therapeutics Market, By Distribution channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Liver Cancer Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Liver Cancer Therapeutics Market.

Available Customizations:

Global Liver Cancer Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Liver Cancer Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Type (Hepatocellular Carcinoma, Cholangiocarcinoma, Liver Metastasis, Hepatoblastoma, Angiosarcoma)
  • 5.2.2. By Therapy (Targeted Therapy, Radiation and Chemotherapy Therapy, Immunotherapy, Others)
  • 5.2.3. By Equipment (Computed Radiography, MRI, Sonography, Others)
  • 5.2.4. By Age (0-18, 18-35, 35-50, 50+)
  • 5.2.5. By Factors (Non-Alcoholic Fatty Liver Disease, Cirrhosis, Excessive Liver Consumption, Others)
  • 5.2.6. By Route of Administration (Oral, Intra-Venous, Others)
  • 5.2.7. By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.8. By Region
  • 5.2.9. By Company (2025)
• 5.3. Market Map

6. North America Liver Cancer Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Type
  • 6.2.2. By Therapy
  • 6.2.3. By Equipment
  • 6.2.4. By Age
  • 6.2.5. By Factors
  • 6.2.6. By Route of Administration
  • 6.2.7. By Distribution channel
  • 6.2.8. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Liver Cancer Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Type
      • 6.3.1.2.2. By Therapy
      • 6.3.1.2.3. By Equipment
      • 6.3.1.2.4. By Age
      • 6.3.1.2.5. By Factors
      • 6.3.1.2.6. By Route of Administration
      • 6.3.1.2.7. By Distribution channel
  • 6.3.2. Canada Liver Cancer Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Type
      • 6.3.2.2.2. By Therapy
      • 6.3.2.2.3. By Equipment
      • 6.3.2.2.4. By Age
      • 6.3.2.2.5. By Factors
      • 6.3.2.2.6. By Route of Administration
      • 6.3.2.2.7. By Distribution channel
  • 6.3.3. Mexico Liver Cancer Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Type
      • 6.3.3.2.2. By Therapy
      • 6.3.3.2.3. By Equipment
      • 6.3.3.2.4. By Age
      • 6.3.3.2.5. By Factors
      • 6.3.3.2.6. By Route of Administration
      • 6.3.3.2.7. By Distribution channel

7. Europe Liver Cancer Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Type
  • 7.2.2. By Therapy
  • 7.2.3. By Equipment
  • 7.2.4. By Age
  • 7.2.5. By Factors
  • 7.2.6. By Route of Administration
  • 7.2.7. By Distribution channel
  • 7.2.8. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Liver Cancer Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Type
      • 7.3.1.2.2. By Therapy
      • 7.3.1.2.3. By Equipment
      • 7.3.1.2.4. By Age
      • 7.3.1.2.5. By Factors
      • 7.3.1.2.6. By Route of Administration
      • 7.3.1.2.7. By Distribution channel
  • 7.3.2. France Liver Cancer Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Type
      • 7.3.2.2.2. By Therapy
      • 7.3.2.2.3. By Equipment
      • 7.3.2.2.4. By Age
      • 7.3.2.2.5. By Factors
      • 7.3.2.2.6. By Route of Administration
      • 7.3.2.2.7. By Distribution channel
  • 7.3.3. United Kingdom Liver Cancer Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Type
      • 7.3.3.2.2. By Therapy
      • 7.3.3.2.3. By Equipment
      • 7.3.3.2.4. By Age
      • 7.3.3.2.5. By Factors
      • 7.3.3.2.6. By Route of Administration
      • 7.3.3.2.7. By Distribution channel
  • 7.3.4. Italy Liver Cancer Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cancer Type
      • 7.3.4.2.2. By Therapy
      • 7.3.4.2.3. By Equipment
      • 7.3.4.2.4. By Age
      • 7.3.4.2.5. By Factors
      • 7.3.4.2.6. By Route of Administration
      • 7.3.4.2.7. By Distribution channel
  • 7.3.5. Spain Liver Cancer Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cancer Type
      • 7.3.5.2.2. By Therapy
      • 7.3.5.2.3. By Equipment
      • 7.3.5.2.4. By Age
      • 7.3.5.2.5. By Factors
      • 7.3.5.2.6. By Route of Administration
      • 7.3.5.2.7. By Distribution channel

8. Asia Pacific Liver Cancer Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Type
  • 8.2.2. By Therapy
  • 8.2.3. By Equipment
  • 8.2.4. By Age
  • 8.2.5. By Factors
  • 8.2.6. By Route of Administration
  • 8.2.7. By Distribution channel
  • 8.2.8. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Liver Cancer Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Type
      • 8.3.1.2.2. By Therapy
      • 8.3.1.2.3. By Equipment
      • 8.3.1.2.4. By Age
      • 8.3.1.2.5. By Factors
      • 8.3.1.2.6. By Route of Administration
      • 8.3.1.2.7. By Distribution channel
  • 8.3.2. India Liver Cancer Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Type
      • 8.3.2.2.2. By Therapy
      • 8.3.2.2.3. By Equipment
      • 8.3.2.2.4. By Age
      • 8.3.2.2.5. By Factors
      • 8.3.2.2.6. By Route of Administration
      • 8.3.2.2.7. By Distribution channel
  • 8.3.3. Japan Liver Cancer Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Type
      • 8.3.3.2.2. By Therapy
      • 8.3.3.2.3. By Equipment
      • 8.3.3.2.4. By Age
      • 8.3.3.2.5. By Factors
      • 8.3.3.2.6. By Route of Administration
      • 8.3.3.2.7. By Distribution channel
  • 8.3.4. South Korea Liver Cancer Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Cancer Type
      • 8.3.4.2.2. By Therapy
      • 8.3.4.2.3. By Equipment
      • 8.3.4.2.4. By Age
      • 8.3.4.2.5. By Factors
      • 8.3.4.2.6. By Route of Administration
      • 8.3.4.2.7. By Distribution channel
  • 8.3.5. Australia Liver Cancer Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Cancer Type
      • 8.3.5.2.2. By Therapy
      • 8.3.5.2.3. By Equipment
      • 8.3.5.2.4. By Age
      • 8.3.5.2.5. By Factors
      • 8.3.5.2.6. By Route of Administration
      • 8.3.5.2.7. By Distribution channel

9. Middle East & Africa Liver Cancer Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Type
  • 9.2.2. By Therapy
  • 9.2.3. By Equipment
  • 9.2.4. By Age
  • 9.2.5. By Factors
  • 9.2.6. By Route of Administration
  • 9.2.7. By Distribution channel
  • 9.2.8. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Liver Cancer Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Type
      • 9.3.1.2.2. By Therapy
      • 9.3.1.2.3. By Equipment
      • 9.3.1.2.4. By Age
      • 9.3.1.2.5. By Factors
      • 9.3.1.2.6. By Route of Administration
      • 9.3.1.2.7. By Distribution channel
  • 9.3.2. UAE Liver Cancer Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Type
      • 9.3.2.2.2. By Therapy
      • 9.3.2.2.3. By Equipment
      • 9.3.2.2.4. By Age
      • 9.3.2.2.5. By Factors
      • 9.3.2.2.6. By Route of Administration
      • 9.3.2.2.7. By Distribution channel
  • 9.3.3. South Africa Liver Cancer Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Type
      • 9.3.3.2.2. By Therapy
      • 9.3.3.2.3. By Equipment
      • 9.3.3.2.4. By Age
      • 9.3.3.2.5. By Factors
      • 9.3.3.2.6. By Route of Administration
      • 9.3.3.2.7. By Distribution channel

10. South America Liver Cancer Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cancer Type
  • 10.2.2. By Therapy
  • 10.2.3. By Equipment
  • 10.2.4. By Age
  • 10.2.5. By Factors
  • 10.2.6. By Route of Administration
  • 10.2.7. By Distribution channel
  • 10.2.8. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Liver Cancer Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cancer Type
      • 10.3.1.2.2. By Therapy
      • 10.3.1.2.3. By Equipment
      • 10.3.1.2.4. By Age
      • 10.3.1.2.5. By Factors
      • 10.3.1.2.6. By Route of Administration
      • 10.3.1.2.7. By Distribution channel
  • 10.3.2. Colombia Liver Cancer Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cancer Type
      • 10.3.2.2.2. By Therapy
      • 10.3.2.2.3. By Equipment
      • 10.3.2.2.4. By Age
      • 10.3.2.2.5. By Factors
      • 10.3.2.2.6. By Route of Administration
      • 10.3.2.2.7. By Distribution channel
  • 10.3.3. Argentina Liver Cancer Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cancer Type
      • 10.3.3.2.2. By Therapy
      • 10.3.3.2.3. By Equipment
      • 10.3.3.2.4. By Age
      • 10.3.3.2.5. By Factors
      • 10.3.3.2.6. By Route of Administration
      • 10.3.3.2.7. By Distribution channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Liver Cancer Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bayer AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bristol Myers Squibb
• 15.3. Merck & Co., Inc.
• 15.4. Exelixis, Inc.
• 15.5. Eisai Co., Ltd.
• 15.6. F. Hoffmann-La Roche Ltd
• 15.7. Pfizer Inc.
• 15.8. Eli Lilly and Company
• 15.9. Novartis AG
• 15.10. AstraZeneca PLC

16. Strategic Recommendations

17. About Us & Disclaimer